IP Library Granted Patent US 7,342,132
Granted Patent B2
US 7,342,132 · App. 11/462,637 · Granted Mar 11, 2008

Formoterol tartrate process and polymorph

Assignee: Sepracor Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,342,132
App. No.
11/462,637
Granted
Mar 11, 2008
Kind
B2
Abstract

A method of preparation of a highly pure salt of R,R-formoterol L-tartrate is disclosed. The process provides the most thermodynamically stable polymorph by recrystallization of a novel polymorph.

Claims (118)

1. A highly pure (R,R)-formoterol L-tartrate composition that exhibits a differential scanning calorimetry pattern substantially the same as the differential scanning calorimetry pattern shown in FIG. 8 and obtained by a process comprising crystallizing a first polymorph (C) of (R,R)-formoterol L-tartrate from aqueous isopropyl alcohol, wherein

(a) 1 part by weight of said first polymorph is dissolved, by warming, in a mixture of about 2 parts by weight isopropyl alcohol and about 2.5 parts by weight water;

(b) from 1.5 to 4 additional parts by weight of isopropyl alcohol are added;

(c) said solution is cooled; and

(d) (R,R)-formoterol L-tartrate is separated from said solution;

said first polymorph having peaks at the diffraction degrees with the intensity shown below in an X-ray powder diffraction pattern:

Peak number

2-Theta

Intensity

1

6.4

100.0

2

9.0

14.4

3

11.1

14.8

4

12.4

13.9

5

12.9

19.7

6

13.5

19.5

7

14.0

15.1

8

15.0

19.7

9

15.4

16.9

10

15.7

18.1

11

16.3

12.8

12

17.5

64.9

13

19.4

47.3

14

19.9

44.8

15

21.3

29.3

16

22.3

31.5

17

22.9

35.8

18

24.1

80.0

19

24.7

17.6

20

25.5

11.3

21

26.0

15.6

22

26.8

9.1

23

27.4

8.5

24

28.4

10.8

25

29.0

8.5

26

30.5

8.1

27

32.7

10.9

28

34.2

7.9

29

35.7

9.3

30

36.4

6.6

31

37.3

7.9

32

37.8

9.1

33

39.3

10.0

34

39.6

11.4

35

41.1

5.7

36

42.3

4.7.

2. The composition of claim 1 , wherein said (R,R)-formoterol L-tartrate is in the form of a crystalline solid consisting of greater than 99.5% by weight of formoterol L-tartrate at least 95% in the polymorphic form of a thermodynamically stable polymorph (A) of (R,R)-formoterol L-tartrate.

Assignments (1)
CHANGE OF NAME Recorded Nov 29, 2010
From: SEPRACOR INC.
To: SUNOVION PHARMACEUTICALS INC.
Reel/Frame 025428/0525 →
Continuity (5)
Continuation 1105226800 · Feb 7, 2005
Continuation 1080699300 · Mar 23, 2004
Continuation 1023820400 · Sep 10, 2002
Continuation 1003718300 · Nov 9, 2001
Related Publication 20060264507A1 · Nov 23, 2006